AIM
The information detailed in this section of the website has been disclosed pursuant to Rule 26 of the AIM Rules for Companies.
Northwest Biotherapeutics, Inc. is registered in the United States and trades on AIM. The rights of shareholders may be different from the rights of shareholders in a UK incorporated company.
The current number of AIM securities in issue is 42,346,187 shares of common stock.
The percentage of AIM securities not in public hands is 61.93%.
As of 6 November 2007, the significant holders were:
|
Percentage of issued shares |
| Toucan Capital |
45.5 |
| Toucan Partners |
6.1 |
| Al Rajhi Holdings |
10.6 |
| Helium Special Situations Fund |
5.4 |
|
